Stoke Therapeutics Stock Forecast, Price & News

Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

Is Stoke Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Stoke Therapeutics stock.
View analyst ratings for Stoke Therapeutics or view top-rated stocks.

How has Stoke Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STOK stock has increased by 13.2% and is now trading at $22.33.
View which stocks have been most impacted by COVID-19.

Are investors shorting Stoke Therapeutics?

Stoke Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,460,000 shares, an increase of 21.8% from the October 31st total of 2,020,000 shares. Based on an average daily trading volume, of 142,400 shares, the short-interest ratio is presently 17.3 days. Approximately 12.4% of the shares of the stock are short sold.
View Stoke Therapeutics' Short Interest.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Stoke Therapeutics.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its earnings results on Monday, November, 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.04.
View Stoke Therapeutics' earnings history.

What price target have analysts set for STOK?

9 Wall Street analysts have issued 12 month price targets for Stoke Therapeutics' stock. Their forecasts range from $35.00 to $76.00. On average, they expect Stoke Therapeutics' stock price to reach $57.00 in the next year. This suggests a possible upside of 155.3% from the stock's current price.
View analysts' price targets for Stoke Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:

• Edward M. Kaye, Chief Executive Officer & Director
• Huw M. Nash, Chief Operating & Business Officer (LinkedIn Profile)
• Stephen J. Tulipano, Chief Financial Officer
• Barry S. Ticho, Chief Medical Officer (LinkedIn Profile)
• Gene Liau, Chief Scientific Officer

Who are some of Stoke Therapeutics' key competitors?

Some companies that are related to Stoke Therapeutics include Insmed (INSM), Arena Pharmaceuticals (ARNA), Arcus Biosciences (RCUS), Galapagos (GLPG), Reata Pharmaceuticals (RETA), ACADIA Pharmaceuticals (ACAD), 23andMe (ME), Hypera (HYPMY), Cytokinetics (CYTK), Amicus Therapeutics (FOLD), Intra-Cellular Therapies (ITCI), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Cryoport (CYRX) and OPKO Health (OPK).
View all of STOK's competitors.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.85%), Geode Capital Management LLC (0.99%), Goldman Sachs Group Inc. (0.47%), Morgan Stanley (0.39%), Voya Investment Management LLC (0.23%) and Renaissance Technologies LLC (0.23%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends for Stoke Therapeutics.

Which institutional investors are selling Stoke Therapeutics stock?

STOK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Morgan Stanley, Citigroup Inc., Two Sigma Investments LP, Voloridge Investment Management LLC, California State Teachers Retirement System, and Victory Capital Management Inc.. Company insiders that have sold Stoke Therapeutics company stock in the last year include Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Huw M Nash, and Stephen J Tulipano.
View insider buying and selling activity for Stoke Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Stoke Therapeutics stock?

STOK stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, HighVista Strategies LLC, Goldman Sachs Group Inc., Cowen AND Company LLC, Two Sigma Advisers LP, UBS Group AG, SG Americas Securities LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Stoke Therapeutics or or view top insider-buying stocks.

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $22.33.

How much money does Stoke Therapeutics make?

Stoke Therapeutics has a market capitalization of $821.54 million. The company earns $-52.24 million in net income (profit) each year or ($2.09) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

Stoke Therapeutics employs 79 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

Where are Stoke Therapeutics' headquarters?

Stoke Therapeutics is headquartered at 45 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at (781) 430-8200 or via email at [email protected].